The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Open accessThe DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and constraints in administration routes. Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last 2 decades, and only one single new agent from a known antifungal class has been approved in the last decade. Nevertheless, there is hope on the horizon, with a number of new antifungal classes in late-stage clinical development. In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroorotate dehydrogenase enzyme inhibitor), opelconazole (a novel triazole optimized for inhalation), and rezafungin (an echinocandin designed to be dosed once weekly). We focus on the mechanism of action and pharmacokinetics, as well as the spectrum of activity and stages of clinical development. We also highlight the potential future role of these drugs and unmet needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix inhibits the inositol acyltransferase Gwt1 which catalyzes and early step in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway, thereby preventing GPI-anchored protein maturation, a process critical for linkages between different components of the fungal cell wall [39,46].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibrexafungerp is another novel agent which inhibits (1→3)-β-D-glucan synthesis at a different site than echinocandins and thus retains activity against many organisms with echinocandin resistance due to FKS mutations, including many strains of C. auris.156”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
The cited source says what the claim attributes to it.
In the citing paper
“It has oral bioavailability of 35–50% and good systemic distribution except for the CNS.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
The cited source says what the claim attributes to it.
In the citing paper
“Ibrexafungerp is currently only FDA approved as oral therapy for vulvovaginal candidiasis, although clinical trials for invasive candidiasis step-down therapy, refractory candidiasis, and C. auris are ongoing.149,156–159”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [156]
In the citing paper
“At the present time there are a handful of investigational agents at different stages of the antifungal development pipeline. Although the majority still target ergosterol (same as azoles) or 1,3-β-D-glucan (same as echinocandins), they also include some novel classes with novel targets and mechanisms [25,39,40].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“an N-linked acyl lipid side-chain [187] that is considered essential for the antifungal activity [188].”
BackgroundThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Self-citationKoehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951 · cited 1×
“In addition, new manifestations of disease in the intensive care population such as coronavirus disease 2019 (COVID-19)-associated aspergillosis [10–13] and mucormycosis [14, 15] are posing major problems because of extensive drug–drug interactions of antifungal drugs [16].”
BackgroundSelf-citationAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 21×
“Candida dubliensis, C. fabianii, C. glabrata, C. inconspicua, C. kefyr, C. krusei, C. lipolytica, C. pulcherrima, C. sojae, and C. tropicalis were also inhibited by MIC values ≤ 0.125 µg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
BackgroundInfluentialChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 1×
“At the same time, the emergence of Candida auris [7], as well as azole-resistant Aspergillus fumigatus [8], and cryptic species that are morphologically indistinguishable by classical methods within main Aspergillus sections [9] pose additional threats to our current antifungal armamentarium.”
BackgroundThe ALS gene family of Candida albicans.
Hoyer, L. L. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)01984-9 · Cited by 540
Candida albicans Cell Wall Proteins
Chaffin, W. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-07 · Cited by 515 · cited 1×
“Glycosylphosphatidylinositol-anchored mannoproteins serve as adhesions that allow fungi to adhere to mucosal and epithelial surfaces within the host prior to colonization and infection [67].”
BackgroundSionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479 · cited 15×
“Candida dubliensis, C. fabianii, C. glabrata, C. inconspicua, C. kefyr, C. krusei, C. lipolytica, C. pulcherrima, C. sojae, and C. tropicalis were also inhibited by MIC values ≤ 0.125 µg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
BackgroundInfluentialHoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470 · cited 1×
“prolificans, where other treatment options are scarce because of pan resistance [2, 4, 176, 177], olorofim may present a “breakthrough” treatment option [151], as it is not only associated with very low MICs but also has antibiofilm activity [178].”
BackgroundSelf-citationThe emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
Hoenigl, M., Seidel, D., Carvalho, A., Rudramurthy, S. M., Arastehfar, A., Gangneux, J.-P., Nasir, N., Bonifaz, A., Araiza, J., Klimko, N., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00237-8 · Cited by 443
Self-citationCOVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., Cornely, O. A., S. Perlin, D., Lass-Flörl, C., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6020091 · Cited by 421 · cited 1×
“Particularly for combination therapy approaches in invasive aspergillosis, opelconazole would be a new therapeutic option of potential great value by achieving high local concentration without systemic drug concentrations and toxicity, specifically attractive for primarily airway invasive aspergillosis in non-neutrope…”
BackgroundSelf-citationCoste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Willger, S. D., Puttikamonkul, S., Kim, K.-H., Burritt, J. B., Grahl, N., Metzler, L. J., Barbuch, R., Bard, M., Lawrence, C. B., & Cramer, R. A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000200 · Cited by 345
The cell wall architecture of Candida albicans wild‐type cells and cell wall‐defective mutants
Kapteyn, J. C., Hoyer, L. L., Hecht, J. E., Müller, W. H., Andel, A., Verkleij, A. J., Makarow, M., Van Den Ende, H., & Klis, F. M. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01729.x · Cited by 328
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303
Functional and Structural Diversity in the Als Protein Family of Candida albicans
Sheppard, D. C., Yeaman, M. R., Welch, W. H., Phan, Q. T., Fu, Y., Ibrahim, A. S., Filler, S. G., Zhang, M., Waring, A. J., & Edwards, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401929200 · Cited by 300
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292 · cited 2×
“time period and will not disappear after successive passage on drug-free media [19, 29].”
BackgroundSelf-citationF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Self-citationPopulation-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)
Alastruey-Izquierdo, A., Mellado, E., Peláez, T., Pemán, J., Zapico, S., Alvarez, M., Rodríguez-Tudela, J. L., Cuenca-Estrella, M., & FILPOP Study Group (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00383-13 · Cited by 276
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270 · cited 1×
“Indeed, a new wave of studies has found the clinical importance of azole tolerance in therapeutic failure [22, 23, 31] and future studies are underway to better understand the underlying mechanism, with the hope of identifying novel targets impairing this mechanism to thwart the emergence of resistance.”
BackgroundUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241 · cited 5×
“Resistance against polyenes is relatively rare and mechanisms are poorly understood [32].”
BackgroundInfluentialSelf-citationPrattes, J., Wauters, J., Giacobbe, D. R., Salmanton-García, J., Maertens, J., Bourgeois, M., Reynders, M., Rutsaert, L., Van Regenmortel, N., Lormans, P., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.014 · Cited by 233
Self-citationPham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · cited 3×
“, short, stubby, abnormally branched hyphae) but not inhibition of growth as used for amphotericin B and the azoles [64, 100].”
BackgroundStructural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223 · cited 1×
“The occurrence of specific mutations in transcription factor/s regulating the drug target render them hyperactive, which is translocated into the nucleus, followed by binding to the promoter of the drug target and its overexpression as a result [39].”
BackgroundCornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., Thompson, G. R., & for the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 215
Self-citationRudramurthy, S. M., Hoenigl, M., Meis, J. F., Cornely, O. A., Muthu, V., Gangneux, J. P., Perfect, J., Chakrabarti, A., & ISHAM, E. A. (2021) · Mycoses · doi:10.1111/myc.13335 · Cited by 205 · cited 2×
“auris, which will potentially constitute a pathogen with limited treatment options because of its multi-drug-resistant nature, potent inhibition was noted [14].”
BackgroundSelf-citationIn Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium Isolates
Arikan, S., Lozano-Chiu, M., Paetznick, V., & Rex, J. H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.327-330.2001 · Cited by 202
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200 · cited 8×
“For example, even with these new options there are still too few antifungal drugs that are well tolerated and with good activity against the Mucorales, with novel treatment options for mucormycosis probably presenting the biggest need currently.”
BackgroundResultInfluentialHope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199 · cited 3×
“Olorofim is metabolized by multiple CYP450 enzymes including CYP3A4 and is thus susceptible to strong CYP3A4 inhibitors and inducers [117].”
BackgroundSelf-citationFungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Chung, D., Barker, B. M., Carey, C. C., Merriman, B., Werner, E. R., Lechner, B. E., Dhingra, S., Cheng, C., Xu, W., Blosser, S. J., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004487 · Cited by 193
Sionov, E., Chang, Y. C., Garraffo, H. M., & Kwon-Chung, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00295-09 · Cited by 179 · cited 2×
“Moreover, numerous studies have also found azole-resistant isolates without mutations in the drug target, which has led to the discovery of new mechanisms and revealing the complexity of azole resistance [24, 25].”
BackgroundWatanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 1×
“The action of manogepix appears to be fungal pathogen specific, as it does not inhibit human inositol acylation by the closest mammalian ortholog, PIGW [64, 72].”
BackgroundThompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163 · cited 4×
“However, the differences with rezafungin occurred on day 5, when both treatment arms had received a similar 400-mg dose [185].”
BackgroundMethodInfluentialSelf-citationSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · cited 3×
“Renal clearance plays a minor role in the excretion of rezafungin with fractions excreted < 1% at all dose concentrations [190].”
BackgroundInfluentialHagiwara, D., Miura, D., Shimizu, K., Paul, S., Ohba, A., Gonoi, T., Watanabe, A., Kamei, K., Shintani, T., Moye-Rowley, W. S., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006096 · Cited by 156 · cited 10×
“Of note, the TR34/TR46 provide an extra binding site for SrbA and, therefore, strains carrying such TRs have an overexpressed CYP51A combined with mutations modulating the binding of the mold-active azoles [43].”
BackgroundInfluentialReview of the Novel Investigational Antifungal Olorofim
Wiederhold, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6030122 · Cited by 155
Self-citationHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundThe Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145 · cited 1×
“In pathogenic yeasts, ABC and MFS transporters are mainly overexpressed by GOF mutations in TAC1 and MRR1, respectively [19, 30, 46].”
BackgroundSelf-citationGarcía‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143 · cited 2×
“an N-linked acyl lipid side-chain [187] that is considered essential for the antifungal activity [188].”
BackgroundIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138 · cited 16×
“Candida dubliensis, C. fabianii, C. glabrata, C. inconspicua, C. kefyr, C. krusei, C. lipolytica, C. pulcherrima, C. sojae, and C. tropicalis were also inhibited by MIC values ≤ 0.125 µg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
BackgroundInfluentialGsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005775 · Cited by 133 · cited 3×
“Expression of CYP51A in A. fumigatus, however, is regulated by the transcription factor SrBA [43].”
BackgroundPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V., Hough, G., Schlosser, M., Bartizal, K., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126 · cited 3×
“Rezafungin was designed to optimize PK properties and avoid hepatotoxicity by reducing degradation while maintaining the potent antifungal activity and safety profile of the echinocandin class [186].”
BackgroundResultInfluentialAstvad, K. M. T., Johansen, H. K., Røder, B. L., Rosenvinge, F. S., Knudsen, J. D., Lemming, L., Schønheyder, H. C., Hare, R. K., Kristensen, L., Nielsen, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01564-17 · Cited by 125 · cited 1×
“[141], non-azole oral agents are needed to treat such infections in an outpatient setting.”
BackgroundInvasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores
Hoenigl, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1342 · Cited by 125
Self-citationJiménez-Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-13 · Cited by 122 · cited 1×
“niger, A terreus, cryptic species [130], and azole-resistant strains [108, 109, 127].”
BackgroundIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundSionov, E., Chang, Y. C., Garraffo, H. M., Dolan, M. A., Ghannoum, M. A., & Kwon-Chung, K. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05502-11 · Cited by 120
Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 118
Sanguinetti, M., Posteraro, B., La Sorda, M., Torelli, R., Fiori, B., Santangelo, R., Delogu, G., & Fadda, G. (2006) · Infection and Immunity · doi:10.1128/iai.74.2.1352-1359.2006 · Cited by 116 · cited 7×
“AFR1 and AFR2 correspond to CDR1 and MDR1 in Cryptococcus [44, 45].”
BackgroundInfluentialJenks, J. D., Salzer, H. J., Prattes, J., Krause, R., Buchheidt, D., & Hoenigl, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s145545 · Cited by 114 · cited 1×
“Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last two decades, and only one single new agent, isavuconazole [17], from a known antifungal class has been approved in the last decade.”
BackgroundSelf-citationContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110 · cited 1×
“glabrata, numerous GOF mutations in PDR1 have been catalogued, which confer azole resistance, a higher virulence, as well as immunoevasion [47, 48].”
BackgroundArastehfar, A., Daneshnia, F., Hilmioğlu-Polat, S., Fang, W., Yaşar, M., Polat, F., Metin, D. Y., Rigole, P., Coenye, T., Ilkit, M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01001-20 · Cited by 110 · cited 1×
“Interestingly, it has been shown that Candida parapsilosis isolates carrying Y132F are associated with a high mortality rate in addition to causing azole therapeutic failure [36, 37].”
BackgroundSelf-citationPfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw214 · Cited by 103 · cited 2×
“Although in vitro susceptibility results are encouraging, further studies are needed to determine the efficacy of rezafungin in the treatment of invasive aspergillosis [192, 199].”
MethodResultBuil, J. B., Rijs, A. J. M. M., Meis, J. F., Birch, M., Law, D., Melchers, W. J. G., & Verweij, P. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx177 · Cited by 101
Lamoth, F., & Alexander, B. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-15 · Cited by 100
Arastehfar, A., Daneshnia, F., Hafez, A., Khodavaisy, S., Najafzadeh, M.-J., Charsizadeh, A., Zarrinfar, H., Salehi, M., Shahrabadi, Z. Z., Sasani, E., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myz124 · Cited by 99
Self-citationJenks, J. D., Reed, S. L., Seidel, D., Koehler, P., Cornely, O. A., Mehta, S. R., & Hoenigl, M. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.005 · Cited by 99 · cited 1×
“prolificans, where other treatment options are scarce because of pan resistance [2, 4, 176, 177], olorofim may present a “breakthrough” treatment option [151], as it is not only associated with very low MICs but also has antibiofilm activity [178].”
BackgroundSelf-citationCastanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98 · cited 1×
“niger, A terreus, cryptic species [130], and azole-resistant strains [108, 109, 127].”
BackgroundAlkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundSelf-citationThomaz, D. Y., de Almeida, J. N., Sejas, O. N. E., Del Negro, G. M. B., Carvalho, G. O. M. H., Gimenes, V. M. F., de Souza, M. E. B., Arastehfar, A., Camargo, C. H., Motta, A. L., et al. (2021) · Journal of Fungi · doi:10.3390/jof7040259 · Cited by 95 · cited 3×
“parapsilosis isolates carrying Y132F in azole-naïve patients, possibly via environmental sources such as the hands of healthcare workers or devices routinely used in the clinic [37].”
BackgroundSelf-citationWring, S. A., Randolph, R., Park, S., Abruzzo, G., Chen, Q., Flattery, A., Garrett, G., Peel, M., Outcalt, R., Powell, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02068-16 · Cited by 94 · cited 1×
“Ibrexafungerp is currently available as an oral formulation (an intravenous formulation is still in phase I developments) and has a good oral absorption with a bioavailability rate of 35–50% and high protein binding of 99% [113, 114].”
BackgroundIbrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91 · cited 1×
“Human data showed a peak plasma concentration within 4–6 h and a linear decline with a mean half-life of approximately 20–30 hours supporting a once-daily dosing strategy [115].”
BackgroundSelf-citationWiederhold, N. P., Locke, J. B., Daruwala, P., & Bartizal, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky280 · Cited by 91 · cited 1×
“fumigatus wild-type and azole-resistant species, respectively [200].”
Self-citationAtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus
Paul, S., Stamnes, M., Thomas, G. H., Liu, H., Hagiwara, D., Gomi, K., Filler, S. G., & Moye-Rowley, W. S. (2019) · mBio · doi:10.1128/mbio.02563-18 · Cited by 91 · cited 4×
“CDR1B is the main ABC transporter found in A. fumigatus, which is controlled by AtrR [49].”
InfluentialJiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89 · cited 1×
“glabrata isolates with FKS mutations [111, 112] (see below for activity).”
BackgroundSpec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz277 · Cited by 88 · cited 2×
“2 Efficacy In a randomized, phase II clinical trial investigating the efficacy, safety, and tolerability of different oral doses of ibrexafungerp in patients with invasive candidiasis, patients were randomized to receive oral step-down therapy after initial echinocandin treatment with either ibrexafungerp or fluconazo…”
BackgroundSelf-citationColley, T., Alanio, A., Kelly, S. L., Sehra, G., Kizawa, Y., Warrilow, A. G. S., Parker, J. E., Kelly, D. E., Kimura, G., Anderson-Dring, L., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02280-16 · Cited by 87 · cited 2×
“In immunocompromised mice, comparable in vivo findings were seen [180].”
BackgroundGebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00178-20 · Cited by 86 · cited 2×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundSelf-citationPfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
Wiederhold, N. P., Law, D., & Birch, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx065 · Cited by 84
Self-citationIn vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz390 · Cited by 82 · cited 1×
“125 μg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
MethodPfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80 · cited 2×
“Manogepix has been reported to lack in vitro activity against C. krusei and some of the Mucorales [65, 77], including variable activity against Rhizopus and Lichtheimia [89, 95], as well as Mucor and Cunninghamella [65, 89].”
BackgroundGhannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · cited 1×
“niger, A terreus, cryptic species [130], and azole-resistant strains [108, 109, 127].”
BackgroundWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80 · cited 1×
“Olorofim was highly active in vitro and in vivo against central nervous system coccidioidomycosis in a mouse model [157].”
BackgroundSelf-citationJenks, J. D., Seidel, D., Cornely, O. A., Chen, S., van Hal, S., Kauffman, C., Miceli, M. H., Heinemann, M., Christner, M., Jover Sáenz, A., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.01.012 · Cited by 80
Self-citationLeonardelli, F., Macedo, D., Dudiuk, C., Cabeza, M. S., Gamarra, S., & Garcia-Effron, G. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00905-16 · Cited by 79 · cited 11×
“Of note, the TR34/TR46 provide an extra binding site for SrbA and, therefore, strains carrying such TRs have an overexpressed CYP51A combined with mutations modulating the binding of the mold-active azoles [43].”
BackgroundInfluentialCass, L., Murray, A., Davis, A., Woodward, K., Albayaty, M., Ito, K., Strong, P., Ayrton, J., Brindley, C., Prosser, J., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.690 · Cited by 78 · cited 5×
“5 and 10 mg in healthy cohort one and repeated doses of 5 mg for 7 days in healthy cohort two [179], the geometric mean plasma Cmax after the 5-mg single dose did not significantly differ between healthy subjects and subjects with mild asthma.”
BackgroundInfluentialThe Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 CountriesPreprint
Hoenigl, M., Seidel, D., Carvalho, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844587 · Cited by 78 · cited 1×
“In addition, new manifestations of disease in the intensive care population such as coronavirus disease 2019 (COVID-19)-associated aspergillosis [10–13] and mucormycosis [14, 15] are posing major problems because of extensive drug–drug interactions of antifungal drugs [16].”
Self-citationDiscovery of a Novel Class of Orally Active Antifungal β-1,3- d -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75
Pfaller, M. A., Duncanson, F., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-11 · Cited by 74
James, K. D., Laudeman, C. P., Malkar, N. B., Krishnan, R., & Polowy, K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-16 · Cited by 73 · cited 2×
“Rezafungin is a chemical analog to anidulafungin with a similar alkoxy triphenyl moiety but a distinct structural modification at the C5 ornithine hemiaminal of the cyclic core, which is replaced by a choline aminal ether [189].”
BackgroundJiménez-Ortigosa, C., Moore, C., Denning, D. W., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01277-17 · Cited by 72
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
Self-citationArendrup, M. C., Jørgensen, K. M., Hare, R. K., & Chowdhary, A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02136-19 · Cited by 70
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 69
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundLackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67
Self-citationSchell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66
Biswas, C., Law, D., Birch, M., Halliday, C., Sorrell, T. C., Rex, J., Slavin, M., & Chen, S. C.-A. (2018) · Medical Mycology · doi:10.1093/mmy/myx161 · Cited by 66
Rivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz078 · Cited by 66
Nunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-19 · Cited by 66 · cited 1×
“glabrata isolates with FKS mutations [111, 112] (see below for activity).”
BackgroundVale-Silva, L., Ischer, F., Leibundgut-Landmann, S., & Sanglard, D. (2013) · Infection and Immunity · doi:10.1128/iai.00074-13 · Cited by 65 · cited 1×
“glabrata isolates carrying GOF mutations in PDR1 are more immunoevasive and less identified by macrophages compared with their wild-type counterparts and paradoxically such isolates are more adherent to epithelial cells, which is mainly due to upregulation of EPA genes [52, 53].”
BackgroundGene Overexpression/Suppression Analysis of Candidate Virulence Factors of Candida albicans
Fu, Y., Luo, G., Spellberg, B. J., Edwards, J. E., & Ibrahim, A. S. (2008) · Eukaryotic Cell · doi:10.1128/ec.00445-07 · Cited by 65
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.028 · Cited by 65
Jenks, J. D., Seidel, D., Cornely, O. A., Chen, S., van Hal, S., Kauffman, C., Miceli, M. H., Heinemann, M., Christner, M., Jover Sáenz, A., et al. (2020) · Mycoses · doi:10.1111/myc.13067 · Cited by 65 · cited 1×
“prolificans, where other treatment options are scarce because of pan resistance [2, 4, 176, 177], olorofim may present a “breakthrough” treatment option [151], as it is not only associated with very low MICs but also has antibiofilm activity [178].”
BackgroundSelf-citationLocke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 64 · cited 1×
“A frontloaded drug exposure suggests advantages in preventing the selection of resistant strains [210].”
BackgroundSatish, S., Jiménez-Ortigosa, C., Zhao, Y., Lee, M. H., Dolgov, E., Krüger, T., Park, S., Denning, D. W., Kniemeyer, O., Brakhage, A. A., et al. (2019) · mBio · doi:10.1128/mbio.00779-19 · Cited by 64
Lepak, A. J., Zhao, M., VanScoy, B., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02154-17 · Cited by 63 · cited 1×
“parapsilosis strains in murine models of immunocompromised disseminated candidiasis [198, 199].”
BackgroundKirchhoff, L., Dittmer, S., Buer, J., Rath, P.-M., & Steinmann, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106105 · Cited by 61
Helleberg, M., Jørgensen, K. M., Hare, R. K., Datcu, R., Chowdhary, A., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02438-19 · Cited by 61
Gebremariam, T., Gu, Y., Alkhazraji, S., Youssef, E., Shaw, K. J., & Ibrahim, A. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00380-22 · Cited by 61
Pfaller, M. A., Hata, K., Jones, R. N., Messer, S. A., Moet, G. J., & Castanheira, M. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.05.001 · Cited by 60 · cited 7×
“For example, even with these new options there are still too few antifungal drugs that are well tolerated and with good activity against the Mucorales, with novel treatment options for mucormycosis probably presenting the biggest need currently.”
BackgroundInfluentialWarrilow, A. G., Nishimoto, A. T., Parker, J. E., Price, C. L., Flowers, S. A., Kelly, D. E., Rogers, P. D., & Kelly, S. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02586-18 · Cited by 60
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., Ramos-Martín, V, Livermore, J., Kolamunnage-Dona, R., Colombo, A. L., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix479 · Cited by 59
Viriyakosol, S., Kapoor, M., Okamoto, S., Covel, J., Soltow, Q. A., Trzoss, M., Shaw, K. J., & Fierer, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01715-18 · Cited by 59 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundGamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58 · cited 2×
“Ibrexafungerp is currently available as an oral formulation (an intravenous formulation is still in phase I developments) and has a good oral absorption with a bioavailability rate of 35–50% and high protein binding of 99% [113, 114].”
BackgroundPrattes, J., Wauters, J., Giacobbe, D. R., Lagrou, K., Hoenigl, M., on behalf of the ECMM-CAPA Study Group, Koehler, P., Salmanton-García, J., Rautemaa-Richardson, R., Hatzl, S., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06471-6 · Cited by 56
Self-citationGeorgacopoulos, O., Nunnally, N. S., Ransom, E. M., Law, D., Birch, M., Lockhart, S. R., & Berkow, E. L. (2021) · Journal of Fungi · doi:10.3390/jof7050378 · Cited by 56
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., McCarthy, D. I., Bocanegra, R., Olivo, M., Kirkpatrick, W. R., Everson, M. P., Duncanson, F. P., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03944-14 · Cited by 55
Self-citationIn vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
Rivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz022 · Cited by 54 · cited 2×
“Manogepix has been reported to lack in vitro activity against C. krusei and some of the Mucorales [65, 77], including variable activity against Rhizopus and Lichtheimia [89, 95], as well as Mucor and Cunninghamella [65, 89].”
BackgroundArendrup, M. C., Chowdhary, A., Astvad, K. M. T., & Jørgensen, K. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-18 · Cited by 53
Singh, A. K., Singh, P., Meis, J. F. G. M., & Chowdhary, A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa562 · Cited by 53 · cited 1×
“Olorofim exhibits no activity for yeast, Exophiala dermatitidis [151], or the Mucorales group [152] of thermally monomorphic molds, and also no activity against Alternaria alternata [153], but does have activity against several clinically important groups of fungi, including dimorphic molds (e.”
BackgroundArastehfar, A., Daneshnia, F., Hilmioglu-Polat, S., Ilkit, M., Yasar, M., Polat, F., Metin, D. Y., Dokumcu, Ü. Z., Pan, W., Hagen, F., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa419 · Cited by 52 · cited 1×
“Indeed, a new wave of studies has found the clinical importance of azole tolerance in therapeutic failure [22, 23, 31] and future studies are underway to better understand the underlying mechanism, with the hope of identifying novel targets impairing this mechanism to thwart the emergence of resistance.”
BackgroundSelf-citationLarkin, E. L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., & Ghannoum, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02611-18 · Cited by 52 · cited 1×
“In another study, ibrexafungerp accumulation was shown in vaginal tissue and fluid with a tissue concentration of twofold to fivefold higher than plasma concentrations and supporting the recent approval for the treatment of Candida vaginitis using a single-day 600-mg treatment (300 mg twice-daily dosage) [118].”
ResultMiesel, L., Cushion, M. T., Ashbaugh, A., Lopez, S. R., & Ong, V. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01992-20 · Cited by 52 · cited 1×
“A significant decrease in the number of trophic nuclei and reduced count of cystic forms have been demonstrated in the rezafungin-treated groups, with a comparable efficacy to the active control trimethoprim-sulfamethoxazole [202].”
ResultVale-Silva, L. A., Moeckli, B., Torelli, R., Posteraro, B., Sanguinetti, M., & Sanglard, D. (2016) · mSphere · doi:10.1128/msphere.00065-15 · Cited by 51 · cited 1×
“glabrata isolates carrying GOF mutations in PDR1 are more immunoevasive and less identified by macrophages compared with their wild-type counterparts and paradoxically such isolates are more adherent to epithelial cells, which is mainly due to upregulation of EPA genes [52, 53].”
BackgroundAstvad, K. M. T., Jørgensen, K. M., Hare, R. K., Datcu, R., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01527-20 · Cited by 51
Pfaller, M. A., Watanabe, N., Castanheira, M., Messer, S. A., & Jones, R. N. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr342 · Cited by 50
Basso, L. R., Gast, C. E., Bruzual, I., & Wong, B. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku554 · Cited by 50 · cited 7×
“AFR1 and AFR2 correspond to CDR1 and MDR1 in Cryptococcus [44, 45].”
BackgroundInfluentialZhao, M., Lepak, A. J., Marchillo, K., Vanhecker, J., Sanchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 50 · cited 2×
“Similarly, the AUC/MEC was the PK/PD target associated with efficacy in a neutropenic murine model of invasive aspergillosis [76].”
BackgroundZhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50
Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49
Miesel, L., Lin, K., & Ong, V. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.546 · Cited by 47 · cited 3×
“parapsilosis strains in murine models of immunocompromised disseminated candidiasis [198, 199].”
BackgroundResultColley, T., Sehra, G., Daly, L., Kimura, G., Nakaoki, T., Nishimoto, Y., Kizawa, Y., Strong, P., Rapeport, G., & Ito, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-45890-w · Cited by 47
Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., Angulo, D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02429-19 · Cited by 47 · cited 1×
“5 mg/ kg bodyweight daily) plus isavuconazole (40 mg/kg bodyweight daily) not only reduced pulmonary fungal burden in a neutropenic rabbit model but also prolonged survival [146].”
BackgroundHodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. P., Van Hoogdalem, E.-J., Kramer, W., & Wedel, P. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1390 · Cited by 45 · cited 1×
“All AEs were, again, mild, transient, and required no specific treatment with headache that most frequently observed [103].”
BackgroundWring, S., Murphy, G., Atiee, G., Corr, C., Hyman, M., Willett, M., & Angulo, D. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.588 · Cited by 45 · cited 1×
“These findings support the coadministration of ibrexafungerp and tacrolimus without the need for an initial dose adjustment for tacrolimus [119].”
ResultWring, S., Borroto-Esoda, K., Solon, E., & Angulo, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02119-18 · Cited by 45 · cited 3×
“Ibrexafungerp is mainly eliminated via feces and is marginally recovered from urine (approximately 1%) [116].”
BackgroundArendrup, M. C., Meletiadis, J., Zaragoza, O., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca-Estrella, M., Mouton, J. W., & Guinea, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.021 · Cited by 45 · cited 3×
“125 μg/mL and were susceptible to other echinocandins using epidemiological cut-off value (ECV) interpretive criteria [194, 195].”
BackgroundMethodMadurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
Lim, W., Eadie, K., Konings, M., Rijnders, B. J. A., Fahal, A. H., Oliver, J. D., Birch, M., Verbon, A., & van de Sande, W. W. J. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz529 · Cited by 45 · cited 1×
“Olorofim has shown excellent in vitro activity against both mold and yeast phases of Talaromyces marneffei [158], and also against Madurella mycetomatis, the main causative agent of eumycetoma [159] as well as dermatophytes including Trichophyton spp.”
BackgroundMarcos-Zambrano, L. J., Gómez-Perosanz, M., Escribano, P., Bouza, E., & Guinea, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx010 · Cited by 44
Jenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C. (2020) · Journal of Fungi · doi:10.3390/jof6040216 · Cited by 44 · cited 1×
“The diagnosis of these breakthrough infections can be challenging even under optimal circumstances, owing to insufficient sensitivities of current diagnostics [6].”
BackgroundSelf-citationPrattes, J., Koehler, P. A., Hoenigl, M., on behalf of the ECMM-CAPA Study Group, Wauters, J., Giacobbe, D. R., Lagrou, K., Salmanton‐García, J., Rautemaa‐Richardson, R., Hatzl, S., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06510-2 · Cited by 44
Self-citationAstvad, K. M. T., Sanglard, D., Delarze, E., Hare, R. K., & Arendrup, M. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-18 · Cited by 43
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Jeon, H. H., Gu, Y., Kapoor, M., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-18 · Cited by 43 · cited 1×
“The in vitro activity of manogepix has also translated into in vivo efficacy when fosmanogepix has been administered in experimental models of candidiasis, cryptococcosis, coccidioidomycosis, aspergillosis, fusariosis, scedosporiosis, and mucormycosis [73, 76, 81, 82, 84, 90, 98, 101].”
BackgroundZhao, Y., Lee, M. H., Paderu, P., Lee, A., Jimenez-Ortigosa, C., Park, S., Mansbach, R. S., Shaw, K. J., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-18 · Cited by 42
Khan, Z., Ahmad, S., Mokaddas, E., Meis, J. F., Joseph, L., Abdullah, A., & Vayalil, S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01926-17 · Cited by 42
Arastehfar, A., Daneshnia, F., Salehi, M., Yaşar, M., Hoşbul, T., Ilkit, M., Pan, W., Hagen, F., Arslan, N., Türk‐Dağı, H., et al. (2020) · Mycoses · doi:10.1111/myc.13104 · Cited by 42 · cited 1×
“It is noteworthy that in some cases mutations found in the hotspot regions does not confer in vitro resistance to echinocandins, while the infected patient experiences echinocandin therapeutic failure [62].”
BackgroundSelf-citationRivero-Menéndez, O., Cuenca‐Estrella, M., & Alastruey‐Izquierdo, A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa351 · Cited by 42
Badali, H., Cañete-Gibas, C. F., Patterson, H. P., Sanders, C. J., Mermella, B., Garcia, V., Mele, J., Fan, H., & Wiederhold, N. P. (2021) · Mycoses · doi:10.1111/myc.13273 · Cited by 41 · cited 8×
“Candida parapsilosis was the least susceptible organism with MICs up to 4 µg/mL [194].”
BackgroundInfluentialSelf-citationArastehfar, A., Kargar, M. L., Mohammadi, S. R., Roudbary, M., Ghods, N., Haghighi, L., Daneshnia, F., Tavakoli, M., Jafarzadeh, J., Hedayati, M. T., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.655069 · Cited by 41 · cited 1×
“Indeed, a new wave of studies has found the clinical importance of azole tolerance in therapeutic failure [22, 23, 31] and future studies are underway to better understand the underlying mechanism, with the hope of identifying novel targets impairing this mechanism to thwart the emergence of resistance.”
BackgroundSelf-citationHodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1370 · Cited by 40 · cited 1×
“Transient headache was the most frequently described AE [102].”
BackgroundZhu, Y. C., Barat, S., Borroto–Esoda, K., Angulo, D., Chaturvedi, S., & Chaturvedi, V. P. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105922 · Cited by 40
Arastehfar, A., Hilmioğlu-Polat, S., Daneshnia, F., Hafez, A., Salehi, M., Polat, F., Yaşar, M., Arslan, N., Hoşbul, T., Ünal, N., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.587278 · Cited by 40
Self-citationBadali, H., Patterson, H. P., Sanders, C. J., Mermella, B., Gibas, C. F. C., Ibrahim, A. S., Shaw, K. J., & Wiederhold, N. P. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02343-20 · Cited by 40
Self-citationArendrup, M. C., & Jørgensen, K. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00429-20 · Cited by 37
Rivero-Menéndez, O., Soto-Debrán, J. C., Cuenca‐Estrella, M., & Alastruey‐Izquierdo, A. (2021) · Journal of Fungi · doi:10.3390/jof7030232 · Cited by 37
Salmanton‐García, J., Koehler, P. A., Kindo, A. J., Falces‐Romero, I., García‐Rodríguez, J., Ráčil, Z., Chen, S. C. ‐., Климко, Н. Н., Désoubeaux, G., Thompson, G. R., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.08.015 · Cited by 36
Self-citationZhang, J., Liu, H., Xi, L., Chang, Y. C., Kwon-Chung, K. J., & Seyedmousavi, S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00256-21 · Cited by 36 · cited 2×
“Olorofim has shown excellent in vitro activity against both mold and yeast phases of Talaromyces marneffei [158], and also against Madurella mycetomatis, the main causative agent of eumycetoma [159] as well as dermatophytes including Trichophyton spp.”
BackgroundBaistrocchi, S. R., Lee, M. J., Lehoux, M., Ralph, B., Snarr, B. D., Robitaille, R., & Sheppard, D. C. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw513 · Cited by 35 · cited 1×
“Additionally, some data suggest cellular persistence of opelconazole in local immune and epithelial cells, which is potentially valuable in terms of use in prophylaxis or enhancement of antifungal activity [181, 182].”
BackgroundArastehfar, A. A., de Almeida, J. N., Perlin, D. S., İlkit, M., Boekhout, T., & Colombo, A. L. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1921695 · Cited by 35
Self-citationJørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32
Schauwvlieghe, A. F. A. D., de Jonge, N., van Dijk, K., Verweij, P. E., Brüggemann, R. J. M., Biemond, B. J., Bart, A., Borne, P. A. V. D., Verbon, A., van der Beek, M. T., et al. (2018) · Mycoses · doi:10.1111/myc.12788 · Cited by 31
Ghannoum, M., Long, L., Isham, N., Hager, C., Wilson, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-19 · Cited by 31
Kirchhoff, L., Dittmer, S., Weisner, A.-K., Buer, J., Rath, P.-M., & Steinmann, J. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa157 · Cited by 31 · cited 1×
“prolificans, where other treatment options are scarce because of pan resistance [2, 4, 176, 177], olorofim may present a “breakthrough” treatment option [151], as it is not only associated with very low MICs but also has antibiofilm activity [178].”
BackgroundBosco-Borgeat, M. E., Mazza, M., Taverna, C. G., Córdoba, S., Murisengo, O. A., Vivot, W., & Davel, G. (2016) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2016.03.003 · Cited by 30
Kimura, G., Nakaoki, T., Colley, T., Rapeport, G., Strong, P., Ito, K., & Kizawa, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00124-17 · Cited by 28 · cited 2×
“Opelconazole showed marked superiority to voriconazole and posaconazole when evaluating the aforementioned parameters and very high dosages of voriconazole and posaconazole were needed to achieve similar results, once more highlighting that the strength of opelconazole is sustained lung retention and persistent antifu…”
BackgroundResultUkai, Y., Kuroiwa, M., Kurihara, N., Naruse, H., Homma, T., Maki, H., & Naito, A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01216-18 · Cited by 28 · cited 1×
“Finally, ATRF is an MFS transporter, which has been found to be controlled by Yap1 in Aspergillus flavus [51].”
BackgroundLiu, Z., Rossi, J. M., & Myers, L. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00968-18 · Cited by 28 · cited 2×
“In pathogenic yeasts, ABC and MFS transporters are mainly overexpressed by GOF mutations in TAC1 and MRR1, respectively [19, 30, 46].”
BackgroundLack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects
Flanagan, S., Goodman, D. B., Jandourek, A., O'Reilly, T., & Sandison, T. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.757 · Cited by 27 · cited 1×
“In addition, a randomized, double-blind, phase I study was conducted in healthy volunteers to evaluate cardiac effects of single doses of intravenous rezafungin [203].”
BackgroundExtended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Wickes, B. L., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01165-19 · Cited by 24 · cited 1×
“fumigatus isolate harboring a TR34/L98H CYP51A mutation [201].”
BackgroundSelf-citationSu, H., Zhu, M., Tsui, C. K. M., van der Lee, H., Tehupeiory-Kooreman, M. C., Zoll, J., Engel, T. G. P., Li, L., Zhu, J., Lu, Z., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02546-20 · Cited by 24 · cited 1×
“fumigatus isolates [151, 165], including CYP51A active mutants and hard-to-treat cryptic species of Aspergillus, such as A.”
BackgroundNyirjesy, P., Alessio, C., Jandourek, A., Lee, J. D., Sandison, T., & Sobel, J. D. (2019) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000473 · Cited by 23 · cited 2×
“A second phase II study, the randomized, multicenter, open-label, sponsor-blinded, active-controlled, dose-ranging RADIANT trial (RADIANT, NCT02733432), was designed to investigate gel and ointment topical formulations of rezafungin for the treatment of acute VVC, with and without a history of recurrence [205].”
BackgroundMethodPrattes, J., Wauters, J., Giacobbe, D. R., Salmanton‐García, J., Maertens, J. A., Bourgeois, M., Reynders, M., Rutsaert, L., Regenmortel, N. V., Lormans, P., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3868099 · Cited by 21
Self-citationPappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.457 · Cited by 17
Extrapolating Antifungal Animal Data to Humans—Is It Reliable?
Stevens, V. M., Mueller, S. W., Reynolds, P., MacLaren, R., & Kiser, T. H. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00370-x · Cited by 12 · cited 1×
“Both in vitro and animal studies of other echinocandins have reported this phenomenon whereby the fungal burden increases at doses above a certain threshold [208].”
BackgroundAlexander, B. D., Cornely, O. A., Pappas, P. G., Miller, R. A., Vázquez, J. A., Ostrosky‐Zeichner, L., Spec, A., Rautemaa‐Richardson, R., Krause, R., Thompson, G. R., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1432 · Cited by 12 · cited 1×
“Of 41 patients who were treated with oral ibrexafungerp for intra-abdominal infection, oropharyngeal or esophageal candidiasis, candidemia, or other forms of invasive candidiasis, 56% were considered as a partial or complete response and 15% as progressive disease [134].”
BackgroundSelf-citationAPX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1217 · Cited by 10 · cited 1×
“However, recent work has demonstrated activity in mouse models against Rhizopus delemar [96], and both in vitro and in vivo activity against Rhizopus arrhizus/oryzae, a frequent cause of mucormycosis in humans [97, 98].”
BackgroundSelf-citationel Helou, S., & Angulo, D. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.08.099 · Cited by 8 · cited 1×
“In a randomized, multicenter, evaluator-blinded study of 96 patients with moderate or severe VVC, patients were randomized to receive oral ibrexafungerp for 3 days, ibrexafungerp for 5 days, or fluconazole [143].”
BackgroundOng, V. S., Sandison, T., & Flanagan, S. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.579 · Cited by 8 · cited 1×
“In healthy subjects, no relevant PK interactions were monitored when dosing rezafungin concomitantly with several probe drugs [191].”
BackgroundBulpa, P. A., Rahav, G., Oren, I., Aoun, M., Thompson, G. R., Pappas, P. G., Kullberg, B. J., Vázquez, J. A., Barbat, S. H., Wedel, P. C., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1343 · Cited by 8
Self-citationAngulo, D., Tufa, M., & Azie, N. E. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.10.088 · Cited by 6
Hoenigl, M., Egger, M., Salmanton‐García, J., Koehler, P. A., Gangneux, J., Arendrup, M. C., Bicanic, T. A., Arıkan-Akdağlı, S., Cornely, O. A., & ECMM Study Group (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.038 · Cited by 6
Self-citationMüller, C., Fietz, C., Koehler, P. A., Sibley, G. E. M., Nforbugwe, A. C. A., Streichert, T., & Wiesen, M. H. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01356-18 · Cited by 4
Carruthers, C., Barat, S., Thomas, P., & Lewis, E. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.10.043 · Cited by 3
Gebremariam, T., Alkhazraji, S., Gu, Y., Alqarihi, A., Mamouei, Z., Shaw, K. J., & Ibrahim, A. S. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz360.794 · Cited by 3
Schwebke, J. R., Sorkin-Wells, V., Azie, N. E., Angulo, D., & Sobel, J. D. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.127 · Cited by 3 · cited 1×
“In the multicenter, randomized, double-blinded VANISH-303 trial [144, 145], patients in the USA were randomized in a 2:1 ratio to treatment with either ibrexafungerp 600 mg once daily or placebo.”
MethodSobel, J. D., Borroto–Esoda, K., Azie, N. E., & Angulo, D. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.126 · Cited by 1
Research works printed but not linked: 9
- Vale-Silva L Ischer F Leibundgut-Landmann S Sanglard D Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells Infect Immun 2013 81 5 1709 1720 10.1128/IAI.00074-13 23460523 PMC3648025 · DOI · Paper page
- Hagiwara D Miura D Shimizu K Paul S Ohba A Gonoi T A novel Zn2-Cys6 transcription factor AtrR plays a key role in an azole resistance mechanism of Aspergillus fumigatus by co-regulating cyp51A and cdr1B expressions PLoS Pathog 2017 13 1 e1006096 10.1371/journal.ppat.1006096 28052140 PMC5215518 · DOI · Paper page
- Ghannoum M, Long L, Larkin EL, Isham N, Sherif R, Borroto-Esoda K, et al. SCY-078, a novel oral glucan synthase inhibitor, for the treatment of invasive aspergillosis: evaluation of antifungal activity singly and in combination. Antimicrob Agents Chemother. 2018;62(6):e00244-18. PMC5971594 29610204 · DOI · Paper page
- Trucksis M, Garrett G, Heriman I. A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011; Chicago (IL).
- Kennedy T AG, Steiner J, Heep M, Oliver J, Sibley G, Law D., editor Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects. In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22–25 April 2017; Vienna.
- Kennedy TAG, Steiner J, Heep M, Oliver J, Sibley G, Law D, editor Assessment of the duraiton of infusion on the tolerability and repaet dose pharmacokinetics of F901318 in health-volunteers (abstract P1711). In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22-25 April 2017; Vienna.
- Tio SH TK, Ng G, Rex JH, Carney D, Slavin M. Olorofim for a case of severe disseminated Lomentospora prolificans infection. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
- Chen S RN, Cunneen S, Cornelissen K, Rex JH, Heath CH, Harvey E. A case of Lomentospora prolificans treated with the novel antifungal olorofim. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
- Harvey EFL, Rex JH, Thompson G. Successful use of the novel antifungal olorofim in the treatment of dissemianted coccidioidomycosis. Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18-21 April 2020; Paris.
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
“review of the new antifungal agents in clinical development the reader is refered to [409].”
BackgroundCOVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Self-citationThe importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Self-citationThe WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation
Casalini, G., Giacomelli, A., & Antinori, S. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00042-9 · Cited by 197
Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1
Hu, X., Yang, P., Chai, C., Liu, J., Sun, H., Wu, Y., Zhang, M., Zhang, M., Liu, X., & Yu, H. (2023) · Nature · doi:10.1038/s41586-023-05856-5 · Cited by 213
Metadata
- Authors
- Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., Wiederhold, N., & Jenks, J. D.
- Affiliations
- Medical University of Graz (AT)
- University of Cologne (DE)
- Hackensack Meridian Health (US)
- Washington University in St. Louis (US)
- University of California Davis Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of California San Diego (US)
- Corresponding author
- Hoenigl, Martin
- ORCID
- Venue
- Drugs
- Published
- 2021-10
- Volume
- 81
- Issue
- 15
- Pages
- 1703-1729
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8501344
- OpenAlex
- W3202074216
- Cited by
- 467
- References
- 188
- Citations by year
- 2026: 78 · 2025: 116 · 2024: 117 · 2023: 98 · 2022: 54 · 2021: 3
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 8 d)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- national institute of allergy and infectious diseases (UL1TR001442)
- Medical University of Graz
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal drug development, fosmanogepix, ibrexafungerp, olorofim, rezafungin, invasive fungal infections, antifungal resistance mechanisms, triterpenoids, triazoles, echinocandins, pharmacokinetics, drug-drug interactions, unmet medical needs
- MeSH terms
- Invasive Fungal Infections, Drug Development, Animals, Antifungal Agents, Drug Interactions, Fungi, Humans, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.